£42.00
Additional information
| Active substance | Pioglitazone |
|---|---|
| Water Retention | Yes |
| Hepatotoxicity | Low risk, but monitoring liver function is recommended |
| Lab Test | Monitoring blood glucose and liver function tests |
| Also known as | Pioglitazone hydrochloride |
| Blood pressure | Could potentially cause fluid retention which might increase blood pressure |
| Trade name | Actos |
| FORM | 28 pills x 15 mg |
| Storage conditions | Store at room temperature, protect from moisture and light |
| Chemical name | 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| Formula | C19H20N2O3S |
| Substance class | Thiazolidinedione |
| Main action | Antidiabetic, insulin sensitizer |
| Half-life | 3-7 hours |
| Dosage (medical) | Typically 15-45 mg per day |
| Dosage (sports) | Not applicable |
| Effects | Lowers blood glucose, increases insulin sensitivity |
| Side effects | Weight gain, edema, heart failure, increased risk of bladder cancer, bone fractures |
| Use in sports | Not typically used in sports |
| Manufacturer | Takeda |
